R01 AI109039/AI/NIAID NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2015	6
2016	8
2017	5
2018	5
2019	1
2020	2
2021	0

1

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis.

Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, Bannasch M, Meadows JM, Chang KO. Pedersen NC, et al. J Feline Med Surg. 2018 Apr;20(4):378-392. doi: 10.1177/1098612X17729626. Epub 2017 Sep 13. J Feline Med Surg. 2018. PMID: 28901812 Free PMC article.

2

Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.

Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC. Kim Y, et al. PLoS Pathog. 2016 Mar 30;12(3):e1005531. doi: 10.1371/journal.ppat.1005531. eCollection 2016 Mar. PLoS Pathog. 2016. PMID: 27027316 Free PMC article.

3

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.

Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S, Meyerholz DK, Kashipathy MM, Battaile KP, Lovell S, Perlman S, Groutas WC, Chang KO. Rathnayake AD, et al. Sci Transl Med. 2020 Aug 19;12(557):eabc5332. doi: 10.1126/scitranslmed.abc5332. Epub 2020 Aug 3. Sci Transl Med. 2020. PMID: 32747425 Free PMC article.

4

Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.

Galasiti Kankanamalage AC, Kim Y, Damalanka VC, Rathnayake AD, Fehr AR, Mehzabeen N, Battaile KP, Lovell S, Lushington GH, Perlman S, Chang KO, Groutas WC. Galasiti Kankanamalage AC, et al. Eur J Med Chem. 2018 Apr 25;150:334-346. doi: 10.1016/j.ejmech.2018.03.004. Epub 2018 Mar 6. Eur J Med Chem. 2018. PMID: 29544147 Free PMC article.

5

Anti-norovirus therapeutics: a patent review (2010-2015).

Galasiti Kankanamalage AC, Weerawarna PM, Kim Y, Chang KO, Groutas WC. Galasiti Kankanamalage AC, et al. Expert Opin Ther Pat. 2016;26(3):297-308. doi: 10.1517/13543776.2016.1153065. Expert Opin Ther Pat. 2016. PMID: 26881878 Free PMC article. Review.

6

Structure-Guided Optimization of Dipeptidyl Inhibitors of Norovirus 3CL Protease.

Rathnayake AD, Kim Y, Dampalla CS, Nguyen HN, Jesri AM, Kashipathy MM, Lushington GH, Battaile KP, Lovell S, Chang KO, Groutas WC. Rathnayake AD, et al. J Med Chem. 2020 Oct 22;63(20):11945-11963. doi: 10.1021/acs.jmedchem.0c01252. Epub 2020 Oct 2. J Med Chem. 2020. PMID: 32945669

7

Recent Advances in the Discovery of Norovirus Therapeutics.

Kim Y, Galasiti Kankanamalage AC, Chang KO, Groutas WC. Kim Y, et al. J Med Chem. 2015 Dec 24;58(24):9438-50. doi: 10.1021/acs.jmedchem.5b00762. Epub 2015 Aug 17. J Med Chem. 2015. PMID: 26258852 Free PMC article. Review.

8

Fexaramine as an entry blocker for feline caliciviruses.

Kim Y, Chang KO. Kim Y, et al. Antiviral Res. 2018 Apr;152:76-83. doi: 10.1016/j.antiviral.2018.02.009. Epub 2018 Feb 15. Antiviral Res. 2018. PMID: 29454892 Free PMC article.

9

Putative structural rearrangements associated with the interaction of macrocyclic inhibitors with norovirus 3CL protease.

Galasiti Kankanamalage AC, Weerawarna PM, Rathnayake AD, Kim Y, Mehzabeen N, Battaile KP, Lovell S, Chang KO, Groutas WC. Galasiti Kankanamalage AC, et al. Proteins. 2019 Jul;87(7):579-587. doi: 10.1002/prot.25682. Epub 2019 Apr 1. Proteins. 2019. PMID: 30883881 Free PMC article.

10

Protein disulfide isomerases as potential therapeutic targets for influenza A and B viruses.

Kim Y, Chang KO. Kim Y, et al. Virus Res. 2018 Mar 2;247:26-33. doi: 10.1016/j.virusres.2018.01.010. Epub 2018 Jan 31. Virus Res. 2018. PMID: 29382552 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results